首页 > 文献资料
-
To explore the therapeutic effect and mechanism of Bushen Huoxue Xiezhuo Decoction (BHXD) in treating minute lesion nephropathy (MLN) in rats. Methods: The MLN model rats established by a single intravenous injection of Adriamycin were divided into the model and the BHXD groups, and a normal group was set up for control. The effects of treatment on renal function, hemorrheologic parameters, renal tissue transforming growth factor β1 (TGF-β1) expression and poly-anion sites on glomerular basement membrane were observed dynamically. Results: After treatment, all the parameters between the BHXD group and the model group were significantly different respectively, morphological observation also showed the pathological changes in the BHXD group were milder than those in the model group. Conclusion: BHXD treatment could markedly improve the renal function, alleviate blood hypercoagulability and hyperviscosity, protect the anion barrier and delay the progression of glomerular fibrosis and sclerosis.
-
Acute myocardial ischemia was induced by intravenous injection of pituitrin, and electroacupuncture (EA) was applied at the Heart and Lung Meridians (HM and LM), 3 points on each meridian. The changes in the left intraventricular pressure (LVP), the maximum rise rate of intraventricular pressure (LVP dp/dtmax), the area of cardiac force loop (ACFL), and the maximum shortening velocity of myocardial contractile element (Vmax) were observed. As a result, there were significant differences in the improvement of LVP, LVP dp/dtmax, ACFL and Vmax between EA at HM and LM. The regulatory action of EA at HM on the myocardial contractile function was significantly better than that of EA at LM, indicating that HM has a close relationship with the myocardial contractile function.
-
静注人免疫球蛋白抗补体活性测定影响因素的探讨
静注人免疫球蛋白(pH 4)(IVIG)是我公司生产的具有多种抗体活性的血液制品,因具有广泛的应用价值而受到临床重视.其低pH值能更好地保证Fc段生物学活性,一般认为少量的IgG多聚体能暴露出Fc段补体结合位点,从而促使抗补体活性(ACA)产生[1-3].ACA是ICIG中一项重要的指标,它指IVIG中IgG多聚体在没有结合抗原的情况下,激活补体的能力.IgG多聚体通过激活补体使补体消耗,从而使机体的免疫防御能力下降.头痛、潮红、颤抖、背痛、恶心是较常见的不良反应症状[4].因此,ACA的高低对IVIG的质量起着至关重要的作用.据文献报道[5],影响AcA的因素可能与IgG多聚体含量、Na+浓度、pH值、葡萄糖的浓度有关.据此,我们进行了研究.另外,还研究发现枸橼酸含量对ACIA也有一定影响.本文就以上因素对其进行实验分析.
-
营养支持加生长抑素对重症胰腺炎的治疗作用
目的了解营养支持和生长抑素对重症胰腺炎的治疗作用.方法近2年来对10例重症胰腺炎给予营养支持和生长激素治疗(治疗组),并与早期仅用TPN支持的10例重症胰腺炎(对照组)进行比较.所有病人均经淀粉酶、B超、CT及腹腔穿刺液确诊,根据APACHEⅡ评分,>9分为重症胰腺炎.结果两组病人各有1例死亡,差异无显著性,但治疗组并发症较少,住院时间缩短,与对照组比较差异有显著性P<0.05.结论1.重症胰腺炎是肠外营养支持的适应证,而轻型胰腺炎可不必给予肠外营养支持,因此急性胰腺炎的临床分级是十分重要的,APACHⅡ评分能较全面地对此作出评价.2.PN能改善重症胰腺炎病人的营养状态,减少胰腺和消化液的分泌,但并不能达到理想的效果.3.生长抑素能明显抑制胰腺及消化道分泌,与PN合用能减少病人并发症发生率,缩短住院时间.4.应注意保护重症胰腺炎的胃肠道粘膜屏障功能,这对阻断或减轻全身炎性反应综合症有重要意义,早期少量口服谷氨酰胺是可取的,且未见增加胰腺负担,有条件者静脉给予足量谷氨酰双肽更好.5.急性胰腺炎病重期给予静脉输注血浆白蛋白十分重要,它能强化PN治疗,及时提高血浆胶体渗透压,发挥白蛋白运输和抗氧化等生理作用.6.手术病人应置空肠造瘘,以便能早期开始肠内营养,要素饮食经空肠给予无明显胰腺刺激作用.合理的营养支持加生长抑素对重症胰腺炎能改善机体营养状态,进一步减少胰腺分泌,降低重症胰腺炎的并发症,缩短住院时间.
-
AIM To compare the effects of intravenous routeand peritoneal route on liver targeted uptake and expression of plasmid delivered by galactoseterminal glyco-poly-L-Iysine (G-PLL). METHOTS The plasmid pTM/MMP-1 which could be expressed in eukaryotic cells was bound to GPLL, and wes then transferred into Wistar rats by intravenous and intraperitoneal injection. The expression and distribution of the plasmid were observed at different time periods by in situ hybridization and immunohistochemistry. RESULTS The plasmid could be expressed significantly within 24 h after being transferred in vivo by both intravenous and intraperitoneal routes. One week later the expression began to decrease, and could still be observed three weeks later. Although both the intravenous and intraperitoneal route could target-specifically deliver the plasmid to the liver, the effect of the former was better as compared to that of the latter. CONCLUSION Intravenous route is better for liver targeted uptake and expression of G-PLL-bound plasmids than the peritoneal route.
-
静脉注射丁丙诺啡舌下片合并东莨菪碱、异丙嗪注射液成瘾一例
患者,男,32 a,未婚,初中文化,因静脉注射丁丙诺啡舌下片(沙菲片)合并东莨菪碱、异丙嗪成瘾3 a,于2006年3月29日入戒毒所.患者系海洛因成瘾者,自2003年3月在毒友的推荐下开始静脉注射沙菲片加东莨菪碱、异丙嗪注射液(俗称"1+1").刚开始使用的日剂量为,沙菲片0.8 mg·d-1,东莨菪碱注射液0.6 mg·d-1,异丙嗪注射液100 mg·d-1,将上述三种药物用生理盐水60 ml稀释后行静脉注射.后剂量逐渐增加至沙菲片2.4 mg·d-1,东莨菪碱注射液1.8 mg·d-1,异丙嗪注射液300 mg·d-1,每日分3次注射.
-
静脉注射海洛因合并佐匹克隆片剂成瘾一例
患者,女,28 a,汉族,未婚,中专毕业,因滥用海洛因成瘾近2 a,于2007年9月6日入劳教所.
-
静脉注射葡萄糖酸钙液致过敏性休克一例
1 病例报告患者,男,41岁,2 d前不明原因全身瘙痒,四肢及躯干起散在风团块.门诊给予扑尔敏4 mg,维生素C 0.2 g,每日3次口服,在服用2 d后,症状仍不消退,再次门诊就诊.随即给予质量浓度为0.1 g/mL的葡萄糖酸钙液20 mL+质量浓度为0.05 g/mL的葡萄糖液20 mL静脉慢速推注,在推注约2 min注射量约5 mL时,患者自觉全身发热,并伴有胸闷、心悸、头晕、欲吐.
-
股静脉穿刺联合静脉推注输血在消化道大出血病人抢救中的应用
建立有效的静脉通路、及时扩充血容量是抢救消化道大出血病人的关键,消化道出血病人因急性失血或慢性长期失血,导致机体处于极度衰竭状态,周围静脉血液循环不良,致使周围静脉穿刺困难,无法达到快速有效补充血容量.我科应用股静脉穿刺联合静脉推注输血抢救100例消化道大出血休克病人,取得了满意效果.现介绍如下.
-
静脉注射普罗帕酮治疗预激综合征并发室上性心动过速病人的护理
预激综合征并发阵发性室上性心动过速是临床上常见的一组心律失常.射频消融术是预激综合征的根治性治疗手段.但是如并发心动过速,药物治疗仍是主要治疗方法,我院从1999年7月-2003年12月应用普罗帕酮注射液治疗预激综合征并发室上性心动过速病人63例,效果较好,但副反应发生率也较高,现将护理体会介绍如下.
-
静脉注射10%葡萄糖酸钙致新生儿软组织骨样钙化2例
新生儿易引起低钙血症,而出现惊厥或其他明显神经肌肉兴奋症状,一般给予补充钙剂.葡萄糖酸钙静脉注射纠正新生儿低钙血症疗效迅速且显著,因此在新生儿科应用较多.葡萄糖酸钙具有强烈的刺激性,外渗可使局部组织变性、坏死.现将我科2例静脉注射10%葡萄糖酸钙后致软组织钙化情况报告如下.
-
静脉输液技术和方法的改进
静脉输液是治疗和抢救病人的一个重要手段,是护理工作的重要技术操作内容.近年来国内外护理学者对静脉输液进行了多项研究,作者对此综述如下.
-
静脉注射免疫球蛋白的临床循证应用
免疫球蛋白的临床应用早可追溯到100多年前.1890年,第一届诺贝尔奖获得者Behring及其同事观察到免疫性血浆可以改善毒素介导的疾病症状[1],由此使免疫球蛋白开始用于临床预防和治疗感染性疾病.
-
临床药师查房英语
Clinical pharmacist:Good morning,how are you feeling today?药师:早上好,今天感觉怎么样?Patient:Not so good,I've been feeling like nausea and vomit since yesterday,just after finished my chemotherapy.患者:不太好,从昨天化疗完成后就一直恶心、想吐.Clinical pharmacist:Ok,let me check your medical order.Yes,the GP(Gemcitabine+Cisplatin) regimen performed yesterday is very good for NSCLC(Non-Small Cell Lung Cancer),but the Cisplatin in the regimen can cause severe nausea and vomit.And I find the doctor has given antiemetic for you: Tropisetron with intravenous injection and Metoclopramide for oral administration three times a day.Did you follow the advice?药师:好吧,让我看看你的医嘱.是的,你用的GP化疗方案确实对非小细胞肺癌有效,但是其中的顺铂也很容易引起恶心呕吐.而且医嘱上也给你开了止吐药了,有静脉给的托烷司琼,还有口服的甲氧氯普胺需要一天吃三次,你是按这种方法用药的吗?
-
间断或连续静脉注射蔗糖铁治疗肾性贫血
目前静脉注射铁剂均为间断法.我科近2年来分别采用连续静脉注射及间断静脉注射给药,观察两种方法的疗效及安全性,现报告如下.
-
静脉注射与静脉滴注蔗糖铁治疗血液透析患者肾性贫血的疗效比较
本研究对静脉注射与静脉滴射蔗糖铁的疗效及安全性用随机、对照的方法进行了比较.一、对象与方法1.对象:40例Hb<90 g/L、血清铁(SF)≤300 μg/L或转铁蛋白饱和度(TSAT)≤25%,2周内未用过静脉铁剂的维持性血液透析患者.